Screener
Relmada Therapeutics, Inc. RLMD Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | As of / March 31, | As of |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,731,401 | $1,568,944 |
| Accrued expenses | 7,160,233 | 4,861,583 |
| Total current liabilities | 12,891,634 | 6,430,527 |
| Stock appreciation rights | 3,738,583 | 1,060,931 |
| Total liabilities | 16,630,217 | 7,491,458 |
| Commitments and Contingencies (See Note 8) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s accrued expenses?
- Relmada Therapeutics, Inc. (RLMD) reported accrued expenses of $7.16M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Relmada Therapeutics, Inc.'s accrued expenses increased by 80.5% year-over-year, from $3.97M to $7.16M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s accrued expenses has grown at a 107.6% compound annual growth rate (CAGR), from $126.2K to $4.86M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Relmada Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude